Caribou Posts Q3 Loss of $26.6M, Cash Falls to $94.8M Amid Strategic Review
CRBU is trading near its 52-week low of $0.403 (0.5% above the low).
Summary
Caribou reported a Q3 2026 net loss of $26.6 million ($0.25 per share) and $94.8 million in cash and securities, down from $142.8 million at year-end 2025, as it runs a strategic-alternatives review after discontinuing its lead CAR-T programs.
Key Events · Earnings and Guidance · CRBU
-
Q3 Loss Narrows to $26.6M
GAAP net loss was $26.6 million, or $0.25 per share, versus $27.5 million, or $0.30 per share, in Q3 2025.
-
Cash Drops to $94.8M
Cash, cash equivalents, and marketable securities fell to $94.8 million at September 30, 2026 from $142.8 million at December 31, 2025 — a $48.0 million decline over nine months.
-
Spending Still Heavy Pre-Cuts
Q3 R&D was $21.3 million and G&A $7.9 million; the October 6 workforce reduction and trial discontinuation are not yet reflected in these results.
-
Strategic Review Has No Timeline
The board is exploring a merger, acquisition, business combination, or dissolution and liquidation, and will not update unless it approves a course of action or the review concludes.
Analysis · CRBU · Life Sciences
The cash burn Caribou is trying to stop is the story here: $94.8 million remained at September 30, down from $142.8 million at year-end 2025, against a $26.6 million quarterly loss. At the current burn rate that is roughly three and a half quarters of runway, which frames how much time the board has to land a merger, sale, or liquidation before the money runs out. The quarter itself was modestly better than a year ago — loss per share of $0.25 versus $0.30 — but the operating numbers are now secondary to the strategic-alternatives process, which the company says it will not update until the board approves a course of action.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBU was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.2M. The 52-week trading range was $0.40 to $2.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.